Université Paris-Sud/Paris XI, Le Kremlin-Bicêtre, France; INSERM, U848, Villejuif, France; Institut Gustave Roussy, Villejuif, France.
Cytokine Growth Factor Rev. 2013 Aug;24(4):311-8. doi: 10.1016/j.cytogfr.2013.05.001. Epub 2013 Jun 17.
Preclinical and clinical findings suggest that tumor-specific immune responses may be responsible--at least in part--for the clinical success of therapeutic regimens that rely on immunogenic cell death (ICD) inducers, including anthracyclines and oxaliplatin. The molecular pathways whereby some, but not all, cytotoxic agents promote bona fide ICD remain to be fully elucidated. Nevertheless, a central role for the endoplasmic reticulum (ER) stress response has been revealed in all scenarios of ICD described thus far. Hence, components of the ER stress machinery may constitute clinically relevant druggable targets for the induction of ICD. In this review, we will summarize recent findings in the field of ICD research with a special focus on ER stress mechanisms and their implication for cancer therapy.
临床前和临床研究结果表明，肿瘤特异性免疫反应可能是依赖免疫原性细胞死亡（ICD）诱导剂（包括蒽环类药物和奥沙利铂）的治疗方案取得临床成功的部分原因。目前仍需充分阐明某些细胞毒性药物而非所有细胞毒性药物促进真正的 ICD 的分子途径。然而，迄今为止描述的 ICD 所有情况下都揭示了内质网（ER）应激反应的核心作用。因此，ER 应激机制的组成部分可能构成诱导 ICD 的临床相关可用药靶点。在这篇综述中，我们将总结 ICD 研究领域的最新发现，特别关注 ER 应激机制及其对癌症治疗的影响。
